Fact of the day

Pooling four randomised trials in 3613 adults with overweight or obesity but no type 2 diabetes, subcutaneous semaglutide produced 11.85% more weight loss than placebo, while gut side effects and dropouts from side effects were markedly more common.

⚠What it shows: Meta-analysis of only four randomised trials totalling 3613 non-diabetic adults with overweight or obesity; trials were relatively short, so durability of weight loss and long-term safety remain untested, and side effects drove significantly more discontinuation.Meta-analysis · Medicine (Baltimore)